60¢sixtycents

Eli Lilly and CompanyLLY

$1,098.57-13.43 (-1.21%)
NYSEHealthcare24:00 UTC

Company snapshot

Market Cap
$984B
Mega-cap
+1110%
2016 — today
10-Year Price
+1391%
2016 — today
52-Week Range
$625.65$1,160.95
Current $1,098.57· 88%

Eli Lilly (est. 1876) researches, develops, and markets human pharmaceuticals globally. Its diabetes portfolio includes Basaglar, the Humalog and Humulin lines, Jardiance, Trajenta, and Trulicity. Oncology offerings feature Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Autoimmune treatments include Olumiant and Taltz. Neurology/pain products include Cymbalta, Emgality, and Zyprexa. Other key assets include Cialis and Forteo. The firm maintains strategic partnerships with Incyte, Boehringer Ingelheim, and others.

Valuation in context

P/E ratio
39.0
Below average
Below the 10-year average
P/B ratio
31.5
Around average
Around the 10-year average
EV / EBITDA
30.6
Above average
Pricier than usual over the last 10 years
Dividend Yield
0.6%
Near historic low
Near historic low — last 10 years
PEG ratio
1.1
Historically cheap
Historically cheap relative to the last 10 years
FCF Yield
1.4%
Below average
Below the 10-year average
Free · No credit card needed

Get alerted when LLY is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.